Bank of New Hampshire Sells 1,020 Shares of Abbott Laboratories (NYSE:ABT)

Bank of New Hampshire lowered its stake in shares of Abbott Laboratories (NYSE:ABT) by 8.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 11,462 shares of the healthcare product maker’s stock after selling 1,020 shares during the quarter. Bank of New Hampshire’s holdings in Abbott Laboratories were worth $1,262,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of ABT. Rappaport Reiches Capital Management LLC boosted its position in shares of Abbott Laboratories by 0.8% in the 4th quarter. Rappaport Reiches Capital Management LLC now owns 12,287 shares of the healthcare product maker’s stock valued at $1,352,000 after purchasing an additional 94 shares during the period. Avion Wealth boosted its position in shares of Abbott Laboratories by 19.4% in the 4th quarter. Avion Wealth now owns 591 shares of the healthcare product maker’s stock valued at $65,000 after purchasing an additional 96 shares during the period. Renaissance Investment Group LLC boosted its position in shares of Abbott Laboratories by 0.7% in the 4th quarter. Renaissance Investment Group LLC now owns 14,204 shares of the healthcare product maker’s stock valued at $1,563,000 after purchasing an additional 100 shares during the period. Drive Wealth Management LLC boosted its position in shares of Abbott Laboratories by 1.5% in the 4th quarter. Drive Wealth Management LLC now owns 6,712 shares of the healthcare product maker’s stock valued at $739,000 after purchasing an additional 100 shares during the period. Finally, Tectonic Advisors LLC lifted its position in Abbott Laboratories by 0.7% during the 4th quarter. Tectonic Advisors LLC now owns 15,160 shares of the healthcare product maker’s stock worth $1,669,000 after acquiring an additional 102 shares during the period. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

Abbott Laboratories stock traded up $0.61 during mid-day trading on Friday, hitting $107.47. 1,271,998 shares of the company were exchanged, compared to its average volume of 5,631,446. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.64 and a quick ratio of 1.16. The business’s 50 day simple moving average is $113.77 and its two-hundred day simple moving average is $107.96. The company has a market capitalization of $186.48 billion, a P/E ratio of 33.22, a PEG ratio of 2.57 and a beta of 0.74. Abbott Laboratories has a 12-month low of $89.67 and a 12-month high of $121.64.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.02. The company had revenue of $9.96 billion during the quarter, compared to the consensus estimate of $9.88 billion. Abbott Laboratories had a return on equity of 20.32% and a net margin of 13.96%. Abbott Laboratories’s revenue was up 2.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.03 earnings per share. Analysts forecast that Abbott Laboratories will post 4.62 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 2.05%. The ex-dividend date is Friday, April 12th. Abbott Laboratories’s dividend payout ratio (DPR) is 68.54%.

Insider Transactions at Abbott Laboratories

In other news, EVP Andrea F. Wainer sold 42,500 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $112.50, for a total transaction of $4,781,250.00. Following the sale, the executive vice president now owns 65,027 shares in the company, valued at $7,315,537.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Andrea F. Wainer sold 42,500 shares of Abbott Laboratories stock in a transaction on Monday, January 29th. The stock was sold at an average price of $112.50, for a total value of $4,781,250.00. Following the transaction, the executive vice president now owns 65,027 shares in the company, valued at $7,315,537.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Andrea F. Wainer sold 12,500 shares of Abbott Laboratories stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total value of $1,500,000.00. Following the completion of the transaction, the executive vice president now owns 78,704 shares in the company, valued at approximately $9,444,480. The disclosure for this sale can be found here. Insiders have sold 56,435 shares of company stock worth $6,451,298 over the last quarter. 1.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on ABT shares. Citigroup increased their price objective on Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Evercore ISI increased their price objective on Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Royal Bank of Canada cut their target price on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating for the company in a research note on Thursday, April 18th. Raymond James reissued a “buy” rating and set a $124.00 target price on shares of Abbott Laboratories in a research note on Wednesday. Finally, Barclays cut their target price on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating for the company in a research note on Monday. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $121.50.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.